Novo Nordisk's Ozempic, or semaglutide, injection was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use for glycemic control in patients with type 2 diabetes.
Novo's type 2 diabetes drug recommended by EMA panel
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.